188 related articles for article (PubMed ID: 28961609)
1. DCOne as an Allogeneic Cell-based Vaccine for Multiple Myeloma.
Leaf RK; Stroopinsky D; Pyzer AR; Kruisbeek AM; van Wetering S; Washington A; Ephraim A; Cole L; Morin A; Jain S; Nahas MR; Apel A; Arnason J; Hamdan A; Rosenblatt J; Avigan D
J Immunother; 2017; 40(9):315-322. PubMed ID: 28961609
[TBL] [Abstract][Full Text] [Related]
2. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
[TBL] [Abstract][Full Text] [Related]
3. Melan-A/MART1 analog peptide triggers anti-myeloma T-cells through crossreactivity with HM1.24.
Christensen O; Lupu A; Schmidt S; Condomines M; Belle S; Maier A; Hose D; Neuber B; Moos M; Kleist C; Terness P; Ho AD; Goldschmidt H; Klein B; Hundemer M
J Immunother; 2009; 32(6):613-21. PubMed ID: 19483648
[TBL] [Abstract][Full Text] [Related]
4. Successful cross-presentation of allogeneic myeloma cells by autologous alpha-type 1-polarized dendritic cells as an effective tumor antigen in myeloma patients with matched monoclonal immunoglobulins.
Yang DH; Kim MH; Lee YK; Hong CY; Lee HJ; Nguyen-Pham TN; Bae SY; Ahn JS; Kim YK; Chung IJ; Kim HJ; Kalinski P; Lee JJ
Ann Hematol; 2011 Dec; 90(12):1419-26. PubMed ID: 21465188
[TBL] [Abstract][Full Text] [Related]
5. Chaetocin enhances dendritic cell function via the induction of heat shock protein and cancer testis antigens in myeloma cells.
Vo MC; Nguyen-Pham TN; Lee HJ; Jung SH; Choi NR; Hoang MD; Kim HJ; Lee JJ
Oncotarget; 2017 Jul; 8(28):46047-46056. PubMed ID: 28512265
[TBL] [Abstract][Full Text] [Related]
6. Targeting heat shock proteins for immunotherapy in multiple myeloma: generation of myeloma-specific CTLs using dendritic cells pulsed with tumor-derived gp96.
Qian J; Wang S; Yang J; Xie J; Lin P; Freeman ME; Yi Q
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8808-15. PubMed ID: 16361569
[TBL] [Abstract][Full Text] [Related]
7. Optimizing dendritic cell vaccine for immunotherapy in multiple myeloma: tumour lysates are more potent tumour antigens than idiotype protein to promote anti-tumour immunity.
Hong S; Li H; Qian J; Yang J; Lu Y; Yi Q
Clin Exp Immunol; 2012 Nov; 170(2):167-77. PubMed ID: 23039887
[TBL] [Abstract][Full Text] [Related]
8. Dendritic cells fused with allogeneic colorectal cancer cell line present multiple colorectal cancer-specific antigens and induce antitumor immunity against autologous tumor cells.
Koido S; Hara E; Homma S; Torii A; Toyama Y; Kawahara H; Watanabe M; Yanaga K; Fujise K; Tajiri H; Gong J; Toda G
Clin Cancer Res; 2005 Nov; 11(21):7891-900. PubMed ID: 16278414
[TBL] [Abstract][Full Text] [Related]
9. Successful generation of sperm protein 17 (Sp17)-specific cytotoxic T lymphocytes from normal donors: implication for tumour-specific adoptive immunotherapy following allogeneic stem cell transplantation for Sp17-positive multiple myeloma.
Chiriva-Internati M; Wang Z; Salati E; Wroblewski D; Lim SH
Scand J Immunol; 2002 Oct; 56(4):429-33. PubMed ID: 12234264
[TBL] [Abstract][Full Text] [Related]
10. Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patients.
Bercovici N; Haicheur N; Massicard S; Vernel-Pauillac F; Adotevi O; Landais D; Gorin I; Robert C; Prince HM; Grob JJ; Leccia MT; Lesimple T; Wijdenes J; Bartholeyns J; Fridman WH; Salcedo M; Ferries E; Tartour E
J Immunother; 2008 Jan; 31(1):101-12. PubMed ID: 18157017
[TBL] [Abstract][Full Text] [Related]
11. Generation of potent antitumor CTL from patients with multiple myeloma directed against HM1.24.
Rew SB; Peggs K; Sanjuan I; Pizzey AR; Koishihara Y; Kawai S; Kosaka M; Ozaki S; Chain B; Yong KL
Clin Cancer Res; 2005 May; 11(9):3377-84. PubMed ID: 15867238
[TBL] [Abstract][Full Text] [Related]
12. Generation of myeloma-specific T cells using dendritic cells loaded with MUC1- and hTERT- drived nonapeptides or myeloma cell apoptotic bodies.
Ocadlikova D; Kryukov F; Mollova K; Kovarova L; Buresdova I; Matejkova E; Penka M; Buchler T; Hajek R; Michalek J
Neoplasma; 2010; 57(5):455-64. PubMed ID: 20568900
[TBL] [Abstract][Full Text] [Related]
13. Tumor lysate-specific cytotoxic T lymphocytes in multiple myeloma: promising effector cells for immunotherapy.
Wen YJ; Min R; Tricot G; Barlogie B; Yi Q
Blood; 2002 May; 99(9):3280-5. PubMed ID: 11964294
[TBL] [Abstract][Full Text] [Related]
14. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
15. Ubiquitinated Proteins Isolated From Tumor Cells Are Efficient Substrates for Antigen Cross-Presentation.
Yu G; Moudgil T; Cui Z; Mou Y; Wang L; Fox BA; Hu HM
J Immunother; 2017 Jun; 40(5):155-163. PubMed ID: 28368960
[TBL] [Abstract][Full Text] [Related]
16. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
[TBL] [Abstract][Full Text] [Related]
17.
Khalaf WS; Garg M; Mohamed YS; Stover CM; Browning MJ
Front Immunol; 2019; 10():1792. PubMed ID: 31428094
[TBL] [Abstract][Full Text] [Related]
18. Antigen-specific in vitro expansion of functional redirected NY-ESO-1-specific human CD8+ T-cells in a cell-free system.
Jakka G; Schuberth PC; Thiel M; Held G; Stenner F; Van Den Broek M; Renner C; Mischo A; Petrausch U
Anticancer Res; 2013 Oct; 33(10):4189-201. PubMed ID: 24122982
[TBL] [Abstract][Full Text] [Related]
19. Synergistic enhancement of antitumor immunity with adoptively transferred tumor-specific CD4+ and CD8+ T cells and intratumoral lymphotactin transgene expression.
Huang H; Li F; Gordon JR; Xiang J
Cancer Res; 2002 Apr; 62(7):2043-51. PubMed ID: 11929823
[TBL] [Abstract][Full Text] [Related]
20. Tumor cells loaded with α-galactosylceramide promote therapeutic NKT-dependent anti-tumor immunity in multiple myeloma.
Hong S; Lee H; Jung K; Lee SM; Lee SJ; Jun HJ; Kim Y; Song H; Bogen B; Choi I
Immunol Lett; 2013; 156(1-2):132-9. PubMed ID: 24148970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
